MRKMerck Sharp & Dohme LLCRunning, no new patients

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Advanced Cancer · Anal Carcinoma · Anal Cancer · Biliary Cancer · Cholangiocarcinoma · Bile Duct Cancer · Neuroendocrine Tumor · Carcinoid Tumor · Endometrial Carcinoma · Endometrial Cancer · Cervical Carcinoma · Cervical Cancer · Vulvar Carcinoma · Vulvar Cancer · Small Cell Lung Carcinoma · Small Cell Lung Cancer (SCLC) · Mesothelioma · Thyroid Carcinoma · Thyroid Cancer · Salivary Gland Carcinoma · Salivary Gland Cancer · Salivary Cancer · Parotid Gland Cancer · Advanced Solid Tumors · Colorectal Carcinoma

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
+1.9

Worry score2

Score over time

Stage: Phase 2
Patients: 1,609 (planned)
Started: Dec 18, 2015
Main results expected: May 4, 2027
Fully finished: May 4, 2027
Results posted: not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

Objective Response Rate (ORR)
Measured over: Up to approximately 10.5 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.

Show details (technical version)

Score inputs

insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

none yet

Trial ID NCT02628067 · record last updated 2025-09-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT02628067) ↗